Background: Plasticity of the ERBB receptor network has been suggested to cause acquired resistance to anti-human epidermal growth factor receptor 2 (HER2) therapies. Thus, we studied whether a novel approach using an ERBB1-3-neutralizing antibody mixture can block these compensatory mechanisms of resistance. Methods: HER2þ cell lines and xenografts (n 6 mice per group) were treated with the ERBB1-3 antibody mixture Pan-HER, trastuzumab/lapatinib (TL), trastuzumab/pertuzumab (TP), or T-DM1. Downregulation of ERBB receptors was assessed by immunoblot analysis and immunohistochemistry. Paired pre-and post-T-DM1 tumor biopsies from patients (n ¼ 11) with HER2-amplified breast cancer were evaluated for HER2 and P-HER3 expression by immunohistochemistry and/or fluorescence in situ hybridization. ERBB ligands were measured by quantitative reverse transcription polymerase chain reaction. Drugresistant cells were generated by chronic treatment with T-DM1. All statistical tests were two-sided. Results: Treatment with Pan-HER inhibited growth and promoted degradation of ERBB1-3 receptors in a panel of HER2þ breast cancer cells. Compared with TL, TP, and T-DM1, Pan-HER induced a similar antitumor effect against established BT474 and HCC1954 tumors, but was superior to TL against MDA-361 xenografts (TL mean ¼ 2026 mm
Pan-HER is a novel antibody mixture identified by a systematic screen of the optimal combination of antibodies simultaneously targeting two nonoverlapping epitopes within each epidermal growth factor receptor (EGFR), HER2 and HER3. Pan-HER exhibits superior activity against a broad panel of cell lines and patientderived xenografts (PDXs) from diverse genetic backgrounds compared with cetuximab, trastuzumab, and the HER3 antibody seribantumab (MM-121) (1, 2) . Treatment with Pan-HER promotes the formation of large clusters of cross-linked receptors on the cell surface, inducing sustained receptor internalization that, over time, reduces recycling and increases degradation of targeted receptors, thus potentially overcoming drug resistance caused by acquired mutations, ERBB ligand overexpression, and/or compensatory ERBB receptor upregulation (3, 4) .
Increased expression of the ERBB ligands EGF, TGFa, BTC, and NRG1 has been shown to reduce the antitumor effect of the HER2 antibody trastuzumab against HER2-overexpressing (HER2þ) breast cancer cells (5) . Furthermore, cells with acquired resistance to trastuzumab express higher ERBB ligand levels and EGFR/HER2 and HER2/HER3 heterodimers (6) . This resistance is anticipated as trastuzumab, which binds to an epitope in domain IV of the HER2 ectodomain, a region uninvolved with receptor dimerization, is unable to prevent ERBB ligand-induced HER2-containing heterodimers (7) . Consistent with this notion, NRG1 has been shown to rescue HER2þ breast cancer cells from the cytotoxic effect of T-DM1, an antibody-drug conjugate where trastuzumab is linked to cytotoxic chemotherapy (8) . The addition of pertuzumab, a monoclonal antibody that binds the dimerization domain II of HER2, overcomes NRG1-induced resistance to trastuzumab and T-DM1 (9, 10) .
Adaptive changes to HER2 blockade with trastuzumab also involve compensatory upregulation and/or activation of ERBB coreceptors. In HR5 and HR6 cells derived from BT474 xenografts with acquired resistance to trastuzumab in vivo, we observed increased levels of phosphorylated/activated EGFR and HER3 (6) . Similar changes were found in a panel of breast cancer cell lines chronically maintained under treatment with trastuzumab (11) . Further, even dual HER2 blockade with trastuzumab and the EGFR/HER2 tyrosine kinase inhibitor (TKI) lapatinib is unable to completely block compensatory HER3 function. In this case, the addition of a neutralizing HER3 antibody was shown to synergize with the combination of trastuzumab and lapatinib against HER2þ xenografts (12) . We hypothesized that the simultaneous blockade of EGFR, HER2, and HER3 with Pan-HER would prevent these escape mechanisms in HER2þ breast cancer cells and tumors.
Methods

Xenograft Studies
Xenograft experiments were conducted using four-week-old female athymic mice (n 6 mice per group). All mouse experiments were approved by the Vanderbilt Institutional Animal Care and Use Committee, protocol No. M/14/028. Detailed analysis of procedures can be found in the Supplementary Methods (available online).
Tumor Biopsies and Patients
Formalin-fixed, paraffin-embedded (FFPE) tumor blocks were from a cohort of patients (n ¼ 11) who had consented to the use of any de-identified tumor tissues for research purposes under the auspices of an institutional review board-approved protocol (Vanderbilt Institutional Review Board No. 160606). Selection criteria is described in the Supplementary Methods (available online).
Statistical Analysis
Paired and unpaired t tests were used to determine statistically significant differences in cell proliferation assays, in vivo tumor growth assays, real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) assays, and H-scores (immunohistochemistry). A P value of less than .05 was considered statistically significant, and all statistical tests were two-sided. Bar graphs show mean 6 SD, unless otherwise stated in the figure legend.
Additional methods are available in the Supplementary Methods (available online).
Results
ERBB Receptor Downregulation and Cell Viability
We first evaluated the growth inhibitory activity of Pan-HER using a panel of seven HER2þ breast cancer cell lines growing in Matrigel-embedded 3D culture (hereafter called 3D Matrigel). MDA-361, MDA-453, HCC1954, UACC893, and SUM190PT cells contain activating mutations in the catalytic (H1047R) or helical domain (E545K) of PIK3CA. All five cell lines with PIK3CA mutations were relatively insensitive to trastuzumab, but growth of four of these cell lines (MDA-361, UACC893, HCC1954, and MDA-453; all P .05) was inhibited by Pan-HER ( Figure 1A ). SUM190PT cells, derived from an inflammatory breast cancer, were refractory to both treatments.
We next compared the efficacy of Pan-HER with that of anti-HER2 drug combinations and T-DM1. Pan-HER was superior to the combination of trastuzumab and pertuzumab (TP) against HER2þ/PIK3CA mutant cells vs untreated control: HCC1954 (mean ¼ 83.45%, SD ¼ 10.09%, vs 15.86%, SD ¼ 10.72%, P < .001), UACC893 (mean ¼ 42.55%, SD ¼ 6.88%, vs 21.82%, SD ¼ 2.40%, P ¼ .01), and MDA-453 (mean ¼ 68.05%, SD ¼ 9.03%, vs 35.08%, SD ¼ 5.33, P ¼ .03) ( Figure 1B ). T-DM1 had the strongest growthinhibitory effect against all cell lines. Growth inhibition induced by Pan-HER was associated with time-dependent internalization and degradation of EGFR, HER2, and HER3 receptors ( Figure 1C) ; Pan-HER-induced ERBB receptor downregulation was more extensive compared with TP or T-DM1 ( Figure 1D ). These results suggest that treatment with Pan-HER diminished cell surface levels of EGFR, HER2, and HER3 independent of PIK3CA mutation status.
ERBB Receptor Downregulation and Inhibition of Tumor Growth In Vivo
We next established BT474, HCC1954, and MDA-361 xenografts in nude mice and compared the in vivo activity of Pan-HER to other approved anti-HER2 therapies. Mice with established tumors measuring at least 500 mm 3 were randomly assigned to treatment with vehicle, trastuzumab and lapatinib (TL), TP, T-DM1, or Pan-HER. All treatments were effective across the panel of xenografts (Figure 2 , A-C). In mice with MDA-361 tumors, Pan-HER and TP were superior to TL (mean tumor volume in mm 3 6 SD; TL mean ¼ 2026 mm 3 , SD ¼ 924 mm 3 , vs Pan-HER mean ¼ 565 mm 3 , SD¼ 499 mm 3 , P ¼ .04) ( Figure 2C ).
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Immunoblot analysis confirmed statistically significant downregulation of EGFR, HER2, and HER3 in MDA-361 and BT474 xenografts (Figures 2D and Supplementary Figure 1A , available online, for MDA-361 and BT474 xenografts, respectively), except for HER2 in HCC1954 xenografts (Supplementary Figure 1B , available online). Altogether, cell surface biotinylation confirmed that Pan-HER enhances internalization of ERBB receptors as a first step in the process of antibody-induced receptor degradation, while immunoblot analysis captures different stages of this process (internalization, endocytosis, and degradation), thus potentially explaining the variability observed on ERBB receptor levels after anti-HER2 treatment of mouse xenografts. After a complete response of BT474 and HCC1954 xenografts, treatment was discontinued and mice were followed for tumor recurrence. Among mice with BT474 xenografts treated with TP, TL, and T-DM1, 25% to 50% of mice exhibited a tumor recurrence within 50 weeks of follow-up, while no xenograft regrowth was observed among mice that had been treated with Pan-HER ( Figure 2A ; Supplementary Table 1, available online). In three mice, HCC1954 xenografts recurred after having achieved a complete response to T-DM1, while the other four mice remained tumor free up to 50 days ( Figure 2B ).
ERBB Receptors and Ligands in Drug-Resistant HER21 Xenografts and Primary Tumors
We and others have previously shown the critical role of HER3 and ERBB ligands in acquired resistance to anti-HER2 therapies (6, (12) (13) (14) . Thus, we examined ERBB receptor and ligand levels by immunohistochemistry (IHC) and qPCR, respectively. BT474 tumors recurring after TP and T-DM1 retained their histological features by hematoxylin and eosin staining, but exhibited statistically significantly higher HER3 (mean H-score 6 SD; untreated Finally, analysis of KM Plotter web utility (accessed January 26, 2017) showed that overexpression of NRG1 and EGF were associated with poor overall survival in a cohort of 129 patients with HER2þ breast cancer (Supplementary Table 2 , available online) (15) . To identify similar correlations in primary tumors, we next analyzed levels of P-HER3, HER2, and NRG1 in a small cohort of 11 matched pre-and post-treatment tumor biopsy pairs from patients with HER2þ breast cancer that had progressed after anti-HER2 therapies including T-DM1 (Supplementary Table 3 ). HER2 expression and amplification were evaluated by IHC and fluorescence in situ hybridization (FISH), respectively. We observed a reduction of HER2 protein levels in seven of 11 (63.6%) post-T-DM1 tumors ( Figure 4A rentheses. Each data point represents mean tumor volume in mm 3 6 SD. Two-tailed paired t tests were performed to calculate P values. In mice bearing BT474 tumors, treatment was discontinued on day 21; mice were then followed up to 400 days for recurrence. D) MDA-361 xenografts were harvested at the end of the treatment, four hours after the last dose of lapatinib and 24 hours after the last dose of any of the antibodies. CR ¼ number of complete responses; EGFR ¼ epidermal growth factor receptor; TL ¼ trastuzumab/lapatinib; TP ¼ trastuzumab/pertuzumab.
ARTICLE
but still exhibited upregulation of P-HER3 and NRG1 mRNA ( Figure 4D ), suggesting they continued to rely on ERBB receptor activation.
NRG1/HER3 Axis in Breast Cancers With Acquired Resistance to Trastuzumab or T-DM1
We next examined whether other cells resistant to anti-HER2 therapies also upregulated NRG1 and HER3. We interrogated HR6 cells derived from a BT474 xenograft that recurred under continuous trastuzumab treatment (6) and generated HCC1954 and UACC893 cells with acquired resistance to T-DM1 (HCC1954-TDR and UACC893-TDR) in vitro. The IC 50 values for T-DM1 were greater than five-, greater than six-, and 600-fold in HR6, UACC893-TDR, and HCC1954-TDR cells, respectively, compared with their drug-sensitive counterparts ( Figure 5A ). All resistant cells had higher HER3, P-HER3, and NRG1 levels compared with their parental controls and maintained robust levels of EGFR and activation of PI3K as evidenced by S473 P-AKT immunoblot analysis of unstimulated cell lysates ( Figure 5 , B and C). Of note, HCC1954-TDR cells expressed almost undetectable levels of HER2 (
Figure 5B Figure 5A and B, available online). Treatment with LJM716 or Pan-HER, but not with TP or T-DM1, markedly reduced secondary mammosphere formation by the drug-resistant cells (Supplementary Figure 5C , available online). This effect was more potent with Pan-HER than with LJM716, and in the case of HCC1954-TDR cells, the inhibition by Pan-HER was complete. These data suggest a causal association between an activated NRG1-HER3 autocrine axis and a drug-resistant population with tumor-initiating capacity.
Pan-HER Action Against Tumors Relying on ERBB Ligand-Mediated Autocrine Signaling
We next tested whether by blocking autocrine ERBB receptor signaling Pan-HER would be effective against cells with acquired resistance to anti-HER2 therapies. Trastuzumab-resistant HR6 cells growing in 3D Matrigel remained sensitive to TL and Pan-A Fold vs GADPH linear scale Figure 2A ).
Right: Histoscores (H-score) were calculated by an expert breast pathologist (MVE) blinded to treatment. Scale bar ¼ 200 mm. Post-TP and post-T-DM1 recurrent tumors displayed higher levels of membrane HER3 and P-HER3 Y1289 compared with untreated BT474 xenografts. Each bar represents the mean H-score 6 SD (n ¼ 3 for T-DM1 recurrent and n ¼ 2 for TP recurrent). Two-tailed paired and unpaired t tests were performed to calculate P values for T-DM1 and TP recurrent tumors, respectively. B and C) mRNA levels of ERBB ligands were measured by quantitative reverse transcription polymerase chain reaction in BT474 and HCC1954 xenografts harvested prior to treatment and after recurrence following treatment with T-DM1 and TP (as in Figure 2 , A and B). Each bar represents mean ERBB ligand transcript level 6 SD relative to GAPDH mRNA (n ¼ 3 for T-DM1 recurrent and n ¼ 2 for TP recurrent). Two-tailed paired and unpaired t tests were performed to calculate P values for T-DM1 and TP recurrent tumors, respectively. TP ¼ trastuzumab/pertuzumab. Figure 6A , available online). However, studies in athymic mice showed that only Pan-HER, but not TL, TP, or T-DM1, arrested HR6 tumor growth (P < .001, P < .001, and P ¼ .03 for Pan-HER vs TL, TP, and T-DM1, respectively) while downregulating EGFR, HER2, HER3, P-HER3, and P-AKT ( Figure 6 , A and B). HR6 xenografts overexpressed NRG1 (P ¼ .05) and TGFa mRNA (P ¼ .03) compared with parental BT474 tumors ( Figure 6C ). Although they maintained HER2 gene amplification (6), IHC with C-terminal and N-terminal HER2 antibodies suggested they contained lower levels of HER2 protein at the plasma membrane ( Figure 6D ). HCC1954-TDR cells were relatively cross-resistant to TL and TP but remained exquisitely sensitive to Pan-HER in vitro (Supplementary Figure 6B , available online). Consistent with these data, HCC1954-TDR tumors established in nude mice responded completely and rapidly to treatment with Pan-HER (P < .001) but had an accelerated growth after treated with TL, TP, or T-DM1 ( Figure 7A and prevent recurrence after up to 200 days of follow-up ( Figure 7A ). Immunoblot analysis of Pan-HER-treated HCC1954-TDR tumor lysates corroborated downregulation of EGFR, HER2, HER3, P-HER3, and P-AKT ( Figure 7B ). NRG1 was the only ERBB ligand upregulated at the mRNA level in HCC1954-TDR tumors ( Figure 7C ), which no longer exhibited HER2 gene amplification as measured by FISH ( Figure 7D ). Loss of HER2 amplification fits the lack of response to T-DM1 whereas their exquisite response to Pan-HER supports the continuous reliance of these drugresistant tumors on auto-activated HER3/EGFR. Taken together, these data suggest that neutralizing antibody mixtures such as Pan-HER could be a feasible therapeutic strategy in solid tumors with acquired resistance to anti-HER2 targeted therapies.
HER (Supplementary
Discussion
The HER2 oncogene product is amplified in approximately 20% of invasive breast cancers. Despite advances in the understanding of HER2 biology that have led to approval of four anti-HER2 drugs and the adoption of dual HER2 blockade as the new relative to GAPDH, beta-actin, and Rplp0 mRNA (n ¼ 11). D) Representative images from two tumors described in (A) comparing HER2:CEN17 ratio measured by fluorescence in situ hybridization and P-HER3 Y1289 quantified by H-score before and after progression on T-DM1. Scale bar ¼ 50 mm. Two-tailed paired t tests were performed to calculate P values for T-DM1 and trastuzumab/pertuzumab recurrent tumors, respectively.
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standard of care in firstline treatment of HER2þ breast cancer, there is a cohort of patients with primary and acquired resistance to HER2-directed therapies. Further, although we can control HER2þ metastatic recurrences for a prolonged period of time, anti-HER2 therapies are still not curative in this setting (17) (18) (19) . Tumor heterogeneity and the plasticity and redundancy of ERBB (HER) receptor family members are among the main reasons for resistance to HER2-targeted therapies (20) . In the present work, HER2þ breast cancer cell lines with acquired resistance to T-DM1 exhibited increased expression and activation of the HER3 coreceptor and its cognate ligand NRG1. This compensatory upregulation of ERBB receptor signaling in HER2þ cells with acquired drug resistance provides targets for alternative treatments. For example, trastuzumab-resistant HR5 and HR6 BT474 tumors with increased expression of EGFR and ERBB ligands respond to the EGFR TKI erlotinib in vivo (6) . Along these lines, Rimm et al. reported that in the large North Central Cancer Treatment Group N9831 clinical trial, adjuvant trastuzumab did not improve the outcome of patients with HER2þ breast cancer that also harbored EGFR overexpression measured by automated quantitative analysis (AQUA) system (21). Narayan et al. also reported similar "ERBB reprogramming," where HER2þ breast cancer cells after chronic exposure to trastuzumab in vitro exhibit upregulation of EGFR and HER3 and enhanced sensitivity to EGFR and HER3 inhibitors (11) . These adaptive changes in ERBB receptor and ligand expression underscore the plasticity of the ERBB network and its role in acquired drug resistance.
In this work, Pan-HER induced ERBB receptor internalization and degradation in a panel of HER2þ breast cancer cell lines and an equivalent antitumor effect against trastuzumab-naïve HER2þ tumors compared with TL, TP, or T-DM1 in vivo. This effect was independent of the PIK3CA mutation status of the tumors, an increasingly recognized mechanism of resistance to anti-HER2 therapies (22) (23) (24) . In xenografts recurring after TP and T-DM1, as well as in cells with acquired drug resistance (HR6 and HCC1954-TDR), we observed high co-expression of HER3 and its ligand NRG1 with the presence of an expanded cancer stem-like fraction, suggesting a causal association between a NRG1-HER3 axis and the resistant phenotype. Similar results were obtained in a small cohort of patients with HER2-overexpressing breast cancer with available pre-and posttreatment biopsies, where HER3 and NRG1 were upregulated upon progression to multiple anti-HER2 therapies, including T-DM1. A role of HER3 in adaptation and acquired resistance to anti-HER2 therapies in breast cancer is well supported by previous reports (13, 25) . A NRG1-HER3 autocrine loop driving drug resistance has also been reported in melanoma, ovarian, head and neck, and prostate cancers (26) (27) (28) (29) (30) (31) . NRG1 has been linked to an increased mammosphere-forming capacity and high MDR1 expression in breast cancer cells, characteristics associated with tumor recurrence and poor prognosis (32, 33) . Expression of H1047R PIK3CA, an activating mutation in the p110a catalytic domain of PI3K, markedly upregulates NRG1 and attenuates the antitumor effect of trastuzumab and lapatinib against HER2þ breast cancer cells (34) , also suggesting that PI3K mutants promote resistance to anti-HER2 drugs by amplifying ligandinduced signaling output of the ERBB receptor network. Further, exogenous NRG1b reduces the cytotoxic activity of T-DM1 in a subset of breast cancer cell lines, and this effect is reversed by the addition of pertuzumab, an antibody that blocks NRG1-induced HER2-HER3 dimerization (10) . In line with this observation, treatment with the HER3-neutralizing antibody LJM716 resensitized NRG1-overexpressing drug-resistant cells to T-DM1 in the study we report herein. Finally, treatment with Pan-HER induced ERBB receptor downregulation and regression of T-DM1-resistant HR6 and HCC1954 tumors, and also prevented tumor recurrences after therapy was stopped.
We recognize that this study has some limitations. For example, in addition to NRG1-HER3 axis overexpression, other mechanisms of could be involved in drug resistance, such as expression of p95HER2, a truncated form of HER2 not recognized by any of the HER2 antibodies (35, 36) . Confirmation that NRG1-HER3 axis overexpression is a major mechanism of escape from T-DM1 and other anti-HER2 therapies will require prospective systematic rebiopsy of a larger number of HER2þ cancers at the time of post-treatment progression and comparison with matched treatment-naïve tumors.
Our results also suggest the possibility that upon resistance to trastuzumab or T-DM1, in some tumors there is marked reduction of HER2 at the plasma membrane and/or a selection of cells without HER2 gene amplification. These scenarios would limit the activity of some treatment sequences such as that of TP after trastuzumab or T-DM1 and of T-DM1 shortly after trastuzumab, for example, because TP and T-DM1 rely on high HER2 expression at the tumor cell membrane in order to exert antibody-dependent, cell-mediated cytotoxicity or adequate internalization for the targeted delivery of chemotherapy, Figure 2 . Numbers of mice per treatment arm are shown in parentheses. Tumor diameters were followed serially with calipers and tumor volumes calculated as described in the "Methods" section. Each data point represents mean tumor volume in mm 3 6 SD. Paired two-tailed t test was used to calculate P values. B)
Xenografts were harvested four hours after the last dose of lapatinib and 24 hours after the last dose of any of the antibodies. Tumor lysates were prepared and analyzed by immunoblotting with the indicated antibodies. C) mRNA levels of ERBB ligands measured by quantitative reverse transcription polymerase chain reaction in untreated BT474 and HR6 xenografts. Each bar represents the mean transcript level 6 SD relative to GAPDH mRNA (n ¼ 6). Two-tailed paired t tests were performed to calculate P values. D) Left: Immunohistochemistry of formalin-fixed paraffin-embedded sections from BT474 and HR6 xenografts using C-terminal and N-terminal HER2 antibodies. Right: Histoscores (H-score) were calculated by an expert breast pathologist (MVE) blinded to tumor type. 
Notes
The study funders had no role in the design of the study; the collection, analysis, or interpretation of the data; the writing of 
